| Vedolizumab as induction and maintenance therapy for ulcerative colitis BG Feagan, P Rutgeerts, BE Sands, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 699-710, 2013 | 2772 | 2013 |
| Vedolizumab as induction and maintenance therapy for Crohn's disease WJ Sandborn, BG Feagan, P Rutgeerts, S Hanauer, JF Colombel, ... New England Journal of Medicine 369 (8), 711-721, 2013 | 2442 | 2013 |
| Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey N Tozun, O Atug, N Imeryuz, HO Hamzaoglu, A Tiftikci, E Parlak, U Dagli, ... Journal of clinical gastroenterology 43 (1), 51-57, 2009 | 194 | 2009 |
| Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials DT Rubin, I Dotan, A DuVall, Y Bouhnik, G Radford-Smith, PDR Higgins, ... The lancet Gastroenterology & hepatology 7 (1), 17-27, 2022 | 92 | 2022 |
| The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease O Yanartas, HT Kani, E Bicakci, I Kilic, M Banzragch, C Acikel, O Atug, ... Neuropsychiatric disease and treatment, 673-683, 2016 | 84 | 2016 |
| Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease Y Yilmaz, E Ulukaya, OO Gul, M Arabul, CB Gul, O Atug, AY Oral, S Aker, ... Clinical biochemistry 42 (9), 802-807, 2009 | 76 | 2009 |
| Association between the presence of brown adipose tissue and non‐alcoholic fatty liver disease in adult humans Y Yilmaz, T Ones, T Purnak, S Ozguven, R Kurt, O Atug, HT Turoglu, ... Alimentary pharmacology & therapeutics 34 (3), 318-323, 2011 | 75 | 2011 |
| Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance Y Yilmaz, E Ulukaya, O Atug, E Dolar European journal of gastroenterology & hepatology 21 (11), 1247-1251, 2009 | 68 | 2009 |
| Melatonin ameliorates methionine‐and choline‐deficient diet‐induced nonalcoholic steatohepatitis in rats V Tahan, O Atug, H Akin, F Eren, G Tahan, O Tarcin, H Uzun, O Ozdogan, ... Journal of pineal research 46 (4), 401-407, 2009 | 68 | 2009 |
| Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease F Eren, R Kurt, F Ermis, O Atug, N Imeryuz, Y Yilmaz Clinical biochemistry 45 (9), 655-658, 2012 | 67 | 2012 |
| Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis A Tiftikci, O Atug, Y Yilmaz, F Eren, FT Ozdemir, S Yapali, O Ozdogan, ... Archives of Medical Research 40 (4), 294-298, 2009 | 45 | 2009 |
| Dipeptidyl peptidase IV inhibitors: therapeutic potential in nonalcoholic fatty liver disease Y YilmazABDEFG, O AtugDEF, O YonalEF, D DumanADE, O OzdoganD, ... Med Sci Monit 15 (4), 5, 2009 | 42 | 2009 |
| Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity Y Yilmaz, O Yonal, F Eren, O Atug, H Over Hamzaoglu Journal of Crohn's and Colitis 5 (5), 402-406, 2011 | 39 | 2011 |
| Incidence rate of anemia in inflammatory bowel diseases Ö Atuğ, HT Kani, M Banzragch, N İmeryüz, H Akın Turk J Gastroenterol 27 (2), 143-148, 2016 | 30 | 2016 |
| Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease Y Yilmaz, O Ozturk, YO Alahdab, E Senates, Y Colak, HL Doganay, ... Digestive and Liver Disease 45 (1), 58-62, 2013 | 29 | 2013 |
| Critical pH level of lye (NaOH) for esophageal injury O Atug, A Dobrucali, RC Orlando Digestive diseases and sciences 54, 980-987, 2009 | 27 | 2009 |
| Preliminary evidence of an association between the functional c‐kit rs6554199 polymorphism and achalasia in a Turkish population YO Alahdab, F Eren, A Giral, F Gunduz, AE Kedrah, O Atug, Y Yilmaz, ... Neurogastroenterology & Motility 24 (1), 27-30, 2012 | 26 | 2012 |
| Association between bactericidal/permeability increasing protein (BPI) gene polymorphism (Lys216Glu) and inflammatory bowel disease H Akın, G Tahan, F Türe, F Eren, Ö Atuğ, V Tahan, İ Hamzaoğlu, ... Journal of Crohn's and Colitis 5 (1), 14-18, 2011 | 25 | 2011 |
| Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease O Atug, V Tahan, F Eren, A Tiftikci, N Imeryuz, HO Hamzaoglu, N Tozun J Gastrointestin Liver Dis 17 (4), 433-437, 2008 | 24 | 2008 |
| Class distance weighted cross-entropy loss for ulcerative colitis severity estimation G Polat, I Ergenc, HT Kani, YO Alahdab, O Atug, A Temizel Annual Conference on Medical Image Understanding and Analysis, 157-171, 2022 | 21 | 2022 |
